| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| LeBlanc Dorian Paul | Chief Financial Officer | C/O LEMAITRE VASCULAR, INC., 63 SECOND AVENUE, BURLINGTON | /s/ Laurie A. Churchill, Attorney-in-fact | 12 Mar 2026 | 0002061481 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | LMAT | Common Stock | Options Exercise | +2 | +0.08% | $0.000000* | 2,400 | 10 Mar 2026 | Direct | F1 | |
| transaction | LMAT | Common Stock | Tax liability | -96 | -4% | $109.20* | 2,302 | 10 Mar 2026 | Direct | F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | LMAT | Dividend Equivalent Rights | Options Exercise | -2 | -18% | $0.000000* | 9 | 10 Mar 2026 | Common Stock | 2 | Direct | F3 |
| Id | Content |
|---|---|
| F1 | Represents shares acquired upon release of dividend equivalent rights, as reported in Table II, on a one-for-one basis. |
| F2 | These shares represent shares withheld by the Issuer to satisfy tax withholding obligations incurred upon the vesting of restricted stock units awarded to the reporting person on March 10, 2025. This transaction is considered an exempt sale pursuant to Rule 16b-3(e) promulgated under the Securities Exchange Act of 1934. |
| F3 | These dividend equivalent rights were released in connection with the vesting of a restricted stock unit award granted on March 10, 2025. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. |